• Explore /
  • Poster
  • / Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.

Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.

Abstract Poster

Authors

null

John C. Byrd

The Ohio State University Comprehensive Cancer Center, Columbus, OH

John C. Byrd , Peter Hillmen , Susan Mary O'Brien , Jacqueline Claudia Barrientos , Nishitha M. Reddy , Steven Coutre , Constantine S. Tam , Stephen P. Mulligan , Ulrich Jäger , Paul M. Barr , Richard R. Furman , Thomas J. Kipps , Patrick Thornton , John M. Pagel , Jan Andreas Burger , Jeffrey Alan Jones , Sandra Dai , Remus N. Vezan , Danelle Frances James , Jennifer R. Brown

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT01578707

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7510)

DOI

10.1200/JCO.2017.35.15_suppl.7510

Abstract #

7510

Poster Bd #

272

Abstract Disclosures

Similar Posters

First Author: Paul M. Barr

First Author: Ian Flinn

First Author: William G. Wierda

First Author: Herbert Aaron Eradat